Trump Administration Proposes Major Overhaul of Pharmaceutical Prior Authorization

The Centers for Medicare & Medicaid Services (CMS) has introduced a proposed rule aimed at significantly overhauling the prior authorization process for prescription pharmaceuticals. The proposal seeks to establish strict recent time limits and transparency requirements to ensure patients receive essential medications without undue delay.

Prior authorization—a practice where health plans require doctors to request special approval before a specific medication is covered—has long been a point of contention in the U.S. Healthcare system. For many, the process results in critical delays, often forcing patients to navigate a complex bureaucratic maze before they can start necessary treatments.

The new proposal focuses on three primary areas of coverage: Medicare, Medicaid, and Affordable Care Act (ACA) exchange plans. By setting definitive deadlines for these approvals, the administration aims to reduce the window of uncertainty that currently leaves both providers and patients in limbo.

Streamlining Access to Essential Medications

At the heart of the proposal is the desire to eliminate the “days or weeks” of waiting that frequently accompany pharmaceutical approvals. CMS Administrator Mehmet Oz emphasized the urgency of the change, stating, “Patients should not have to wait days or weeks for approval to start the medication their doctor prescribed.”

The proposed rule intends to move prior authorization into a more efficient framework, limiting the time insurance companies can take to respond to a request. This is particularly vital for patients with acute or chronic conditions where a delay in medication can lead to a worsening of health outcomes.

According to reports from Bloomberg Law, the move comes amid growing frustration with insurance companies and their use of restrictive authorization protocols to manage costs.

Addressing the Barriers of “Step Therapy”

A significant pain point within the current prior authorization system is the requirement for patients to strive cheaper, alternative medications before the plan will approve the drug specifically prescribed by their physician. This practice, often referred to as “step therapy,” can be frustrating for patients who have already determined through clinical experience that cheaper alternatives are ineffective or cause adverse reactions.

The proposed CMS rule aims to address these barriers by increasing transparency and imposing restrictions on how these authorizations are handled. By requiring clearer guidelines and faster turnaround times, the rule seeks to prioritize clinical necessity over administrative cost-saving measures.

The overhaul is part of a broader effort by the Trump administration to reduce the friction between healthcare providers and payers, ensuring that medical decisions remain primarily in the hands of doctors and their patients.

A Broader Strategy for Drug Transparency

This recent proposal does not exist in a vacuum but is part of a larger sequence of regulatory actions. On September 2, 2025, the Department of Health and Human Services (HHS) announced changes designed to ease approval processes and enhance prescription drug price transparency via an official HHS rule.

Together, these initiatives represent a systemic push to make the pharmaceutical pipeline more predictable. By combining price transparency with strict authorization deadlines, the administration is attempting to tackle both the cost and the accessibility of prescription drugs simultaneously.

Industry analysts suggest that if these proposed deadlines are finalized, insurance providers will be forced to modernize their internal review processes, potentially leveraging more automation to meet the new CMS mandates.

Key Impacts of the Proposed Rule

• For Patients: Reduced waiting periods to start prescribed medications and fewer forced trials of ineffective “cheaper alternatives.”
• For Providers: Less administrative burden and reduced time spent appealing denied authorization requests.
• For Insurers: A requirement to adhere to strict federal timelines and provide greater transparency regarding their authorization criteria.

As the rule moves toward potential finalization, the healthcare industry will be watching closely to see how these deadlines are defined and what penalties will be imposed on plans that fail to meet them. Further details on the specific number of days allowed for approval are expected as the proposal progresses through the regulatory pipeline, as noted by Fierce Healthcare.

The next official checkpoint will be the public comment period and the subsequent review by CMS before a final rule is issued. We will continue to monitor these filings for specific deadline dates and implementation timelines.

Do you believe stricter deadlines will truly end the frustration of prior authorizations, or will insurance companies find new ways to delay care? Share your thoughts in the comments below.